E-LIB Suche - Ergebnisse für: Brendan, Boyle

1

ASSESSING THE CLINICAL IMPACTS OF IMMUNOMODULATORY WITHDRAW..:

Iovino, Nicholas ; Boyle, Brendan ; McClinchie, Madeline...
Inflammatory Bowel Diseases. 30 (2024) Supplement_1 - p. S70-S71 , 2024

Link: https://doi.org/10.1093/..

2

Suspicion, inclusive leadership and team innovation: A moti..:

Mitchell, Rebecca ; Gu, Jun ; Boyle, Brendan
Journal of Business Research. 172 (2024) - p. 114399 , 2024

Link: https://doi.org/10.1016/..

3

INFLIXIMAB MARKET SHARE AND ASSOCIATED COST SAVINGS FOLLOWI..:

Paglinco, Samantha ; Abdel-Rasoul, Mahmoud ; McNicol, Megan...
Inflammatory Bowel Diseases. 30 (2024) Supplement_1 - p. S51-S51 , 2024

Link: https://doi.org/10.1093/..

4

PREDICTORS OF PRIMARY NON-RESPONSE AND DRUG DURABILITY FOR ..:

Davidson, Nicole ; Morris, Grant ; Wright, Molly...
Inflammatory Bowel Diseases. 30 (2024) Supplement_1 - p. S73-S73 , 2024

Link: https://doi.org/10.1093/..

5

Suspicion, inclusive leadership and team innovation: A moti..:

Mitchell, Rebecca ; Gu, Jun ; Boyle, Brendan
Journal of Business Research. 172 (2024) - p. 114399 , 2024

Link: https://doi.org/10.1016/..

6

GROWTH OUTCOMES OF IV ANTI-TNF BIOSIMILARS IN PEDIATRIC INF..:

McClinchie, Madeline ; Lakhani, Alyshah ; Abdel-Rasoul, Mahmoud...
Inflammatory Bowel Diseases. 29 (2023) Supplement_1 - p. S61-S62 , 2023

Link: https://doi.org/10.1093/..

7

NON-MEDICAL SWITCHING FROM INFLIXIMAB TO A BIOSIMILAR IN AD..:

McNicol, Megan ; Abdel-Rasoul, Mahmoud ; Morris, Grant...
Inflammatory Bowel Diseases. 29 (2023) Supplement_1 - p. S62-S62 , 2023

Link: https://doi.org/10.1093/..

8

GROWTH OUTCOMES OF IV ANTI-TNF BIOSIMILARS IN PEDIATRIC INF..:

McClinchie, Madeline ; Lakhani, Alyshah ; Abdel-Rasoul, Mahmoud...
Gastroenterology. 164 (2023) 4 - p. S78 , 2023

Link: https://doi.org/10.1053/..

9

Barriers to vaccination in immunocompromised children: A ne..:

Lloyd, Audrey R. ; Ardura, Monica I. ; Wise, Kelly...
Frontiers in Pediatrics. 11 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

10

NON-MEDICAL SWITCHING FROM INFLIXIMAB TO A BIOSIMILAR IN AD..:

McNicol, Megan ; Abdel-Rasoul, Mahmoud ; Morris, Grant...
Inflammatory Bowel Diseases. 29 (2023) Supplement_1 - p. S62-S62 , 2023

Link: https://doi.org/10.1093/..

11

GROWTH OUTCOMES OF IV ANTI-TNF BIOSIMILARS IN PEDIATRIC INF..:

McClinchie, Madeline ; Lakhani, Alyshah ; Abdel-Rasoul, Mahmoud...
Inflammatory Bowel Diseases. 29 (2023) Supplement_1 - p. S61-S62 , 2023

Link: https://doi.org/10.1093/..

12

What do they think of me? Professional diversity, meta‐ster..:

Mitchell, Rebecca ; Gu, Jun ; Boyle, Brendan
Human Resource Management Journal. 32 (2022) 4 - p. 864-889 , 2022

Link: https://doi.org/10.1111/..

13

REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN ID..:

Colman, Ruben ; Mizuno, Tomoyuki ; Hyams, Jeffrey...
Gastroenterology. 162 (2022) 3 - p. S100 , 2022

Link: https://doi.org/10.1053/..

14

EQUIVALENT ADVERSE OUTCOMES FOR HOME AND HOSPITAL-BASED INF..:

Gupta, Shivani ; Bricker, Josh ; Boyle, Brendan...
Gastroenterology. 162 (2022) 3 - p. S1 , 2022

Link: https://doi.org/10.1053/..

15

Postcolectomy Enteritis in a Pediatric Patient With Ulcerat..:

Hawa, Kathryn ; Maltz, Ross ; Donegan, Amy...
JPGN Reports. 3 (2022) 4 - p. e255 , 2022

Link: https://doi.org/10.1097/..